CAM-Cytarabine, Aclarubicin Plus Macrophage Colony-Stimulating Factor in the Treatment of Acute Myelogenous Leukemia with Trilineage Dysplasia: Usefulness of in Vitro Apoptosis in Leukemic Cells

Masaki Mori Department of Hematolog, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Kawachi, Tochigi, 329-0498, Japan

Kiyohiko Hatake Department of Hematolog, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Kawachi, Tochigi, 329-0498, Japan; Department of Medical Oncology, Cancer Institute Hospital, at Japanese Foundation for Cancer Research, 1–37–1 Kami-Ikebukuro, Toshima-ku, Tokyo, 170-8455, JapanCorrespondence[email protected]

Masaru Tanaka Department of Hematolog, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Kawachi, Tochigi, 329-0498, Japan

Masaaki Takatoku Department of Hematolog, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Kawachi, Tochigi, 329-0498, Japan

Yuko Matsumoto Department of Hematolog, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Kawachi, Tochigi, 329-0498, Japan

Mie Ucjhida Department of Hematolog, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Kawachi, Tochigi, 329-0498, Japan

Minako Kametaka Department of Hematolog, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Kawachi, Tochigi, 329-0498, Japan

Tadashi Nagai Department of Hematolog, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Kawachi, Tochigi, 329-0498, Japan

Yasuhito Terui Department of Hematolog, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Kawachi, Tochigi, 329-0498, Japan

Hiroshi Tomeuka Department of Hematolog, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Kawachi, Tochigi, 329-0498, Japan

Kazuo Muroi Department of Hematolog, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Kawachi, Tochigi, 329-0498, Japan

Keiya Ozawa Department of Hematolog, Jichi Medical School, 3311-1 Yakushiji, Minamikawachi, Kawachi, Tochigi, 329-0498, Japan

show all

Abstract

A 67-year-old woman was treated for acute myelogenous leukemia with trilineage dysplasia (AML-TLD) by combination chemotherapy with cytarabine, aclarubicin plus macrophage colony-stimulating factor (M-CSF) (referred to as CAM therapy). Complete remission was achieved after two courses of CAM therapy. After coculture of her bone marrow mononuclear cells with M-CSF in vitro, differentiation of leukemic cells into macrophages with apoptotis was observed. This case confirms an earlier report that an effect of M-CSF inducible by differentiation with apoptotic phenomena, against human leukemic cells was shown both in vitro and in vivo when achieving complete remission.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

CAM-Cytarabine, Aclarubicin Plus Macrophage Colony-Stimulating Factor in the Treatment of Acute Myelogenous Leukemia with Trilineage Dysplasia: Usefulness of in Vitro Apoptosis in Leukemic Cells

Information for

Open access

Opportunities

Help and information

CAM-Cytarabine, Aclarubicin Plus Macrophage Colony-Stimulating Factor in the Treatment of Acute Myelogenous Leukemia with Trilineage Dysplasia: Usefulness of in Vitro Apoptosis in Leukemic Cells

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature